Statements (35)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2016
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
N03AX23
|
| gptkbp:CASNumber |
357336-20-0
|
| gptkbp:chemicalFormula |
C11H20N2O2
|
| gptkbp:drugClass |
anticonvulsant
|
| gptkbp:eliminationHalfLife |
7-8 hours
|
| gptkbp:genericName |
gptkb:brivaracetam
|
| https://www.w3.org/2000/01/rdf-schema#label |
Briviact
|
| gptkbp:interactsWith |
gptkb:rifampin
gptkb:carbamazepine gptkb:levetiracetam |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:UCB
|
| gptkbp:mechanismOfAction |
selective synaptic vesicle protein 2A (SV2A) ligand
|
| gptkbp:metabolism |
hepatic
|
| gptkbp:pregnancyCategory |
C
|
| gptkbp:prescribes |
adults
children 4 years and older |
| gptkbp:proteinBinding |
~17.5%
|
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
nausea
dizziness fatigue somnolence |
| gptkbp:UNII |
6H8NS5000B
|
| gptkbp:usedFor |
epilepsy
partial-onset seizures |
| gptkbp:bfsParent |
gptkb:UCB_Biopharma
gptkb:Brivaracetam gptkb:UCB_Pharma |
| gptkbp:bfsLayer |
7
|